Top Abstract Purchase Related
Home
>
Node
>
Subnode

Suppression of lymphocyte activation by a factor produced by Mycoplasma arginini

Callewaert, D.M.; Kaplan, J.; Peterson, W.D.; Lightbody, J.J.

Journal of Immunology 115(6): 1662-1664

1975

ISSN/ISBN: 0022-1767
PMID: 127011
Document Number: 84811
Mycoplasma arginini, when grown in broth or in cultures of human lymphoblast cell lines, inhibits activation of lymphocytes by allogeneic cells of mitogens. This inhibition can also be produced by cell free media obtained after the growth of this organism. Inhibition is not species specific and inhibits both B and T cell activation in the mouse. The inhibitory factor is required during the first 3 days of the mixed leukocyte culture, but has no effect on the latter phase of this reaction when thymidine uptake is greatest. The factor is stable to treatment at 60 degrees, but not 90 degrees, for 30 min.

Document emailed within 1 workday
Secure & encrypted payments

Yang, G.; Coffman, F.D.; Wheelock, E.F. 1994: Characterization and purification of a macrophage-triggering factor produced in Mycoplasma arginini-infected L5178Y cell cultures Journal of Immunology 153(6): 2579-2591
Shchebliakov, D.V.; Logunov, D.I.; Zubkova, O.V.; Shmarov, M.M.; Rakovskaia, I.V.; Naroditskiĭ, B.S.; Gintsburg, A.L.; Gudkov, A.V. 2008: Mycoplasma M. arginini infection induces constitutive activation of NF-kappaB and inhibits apoptosis in cells expressing toll-like receptors TLR2/6 Molekuliarnaia Genetika Mikrobiologiia i Virusologiia 4: 6-10
Locigno, R.; Antoine, N.; Bours, V.; Daukandt, M.; Heinen, E.; Castronovo, V. 2000: TNP-470, a potent angiogenesis inhibitor, amplifies human T lymphocyte activation through an induction of nuclear factor-kappaB, nuclear factor-AT, and activation protein-1 transcription factors Laboratory Investigation; A Journal of Technical Methods and Pathology 80(1): 13-21
Brostoff, J.; Pack, S.; Lydyard, P.M. 1980: Histamine suppression of lymphocyte activation Clinical and Experimental Immunology 39(3): 739-745
Ruuth, E.; Wieslander, A.; Persson, H.; Friedrich, B.; Lundgren, E. 1984: Lymphokine-like activity of a strain of Mycoplasma arginini Israel Journal of Medical Sciences 20(9): 886-890
Miller, G.G.; Rakovskaia, I.V.; Pokidysheva, L.N.; Korablina, E.V.; Titova, I.V. 2009: Mechanisms of interaction between HIV and Mycoplasma arginini in vitro Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 4: 49-53
Leach, R.H. 1970: The occurrence of Mycoplasma arginini in several animal hosts Veterinary Record 87(11): 319-320
Edwards, A.J. 1974: Lymphocyte depressive factor produced by a gut cancer Annals of the Royal College of Surgeons of England 54(6): 270
Hadden, J.W.; Sadlik, J.R.; Hadden, E.M. 1978: The induction of macrophage proliferation in vitro by a lymphocyte-produced factor Journal of Immunology 121(1): 231-238
Sundar, S.K.; Bergeron, J.; Menezes, J. 1984: Purified plasminogen activating factor produced by malignant lymphoid cells abrogates lymphocyte cytotoxicity Clinical and Experimental Immunology 56(3): 701-708
Lazarovits, A.I.; Moscicki, R.A.; Kurnick, J.T.; Camerini, D.; Bhan, A.K.; Baird, L.G.; Erikson, M.; Colvin, R.B. 1984: Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen Journal of Immunology 133(4): 1857-1862
Kelly, R.H.; Wolstencroft, R.A.; Dumonde, D.C.; Balfour, B.M. 1972: Role of lymphocyte activation products (LAP) in cell-mediated immunity. II. Effects of lymphocyte activation products on lymph node architecture and evidence for peripheral release of LAP following antigenic stimulation Clinical and Experimental Immunology 10(1): 49-65
Cerdan, C.; Razanajaona, D.; Martin, Y.; Courcoul, M.; Pavon, C.; Mawas, C.; Olive, D.; Birg, F. 1992: Contributions of the CD2 and CD28 T lymphocyte activation pathways to the regulation of the expression of the colony-stimulating factor (CSF-1) gene Journal of Immunology 149(2): 373-379
Paul, S.; Mehrotra, N.N.; Jailkhani, B.L. 1982: Suppression of lymphocyte reactivity to phytohemagglutinin & mixed lymphocyte culture by human placental syncytiotrophoblast Indian Journal of Experimental Biology 20(3): 204-208
Okada, M.; Henney, C.S. 1980: The differentiation of cytotoxic T cells in vitro. II. Amplifying factor(s) produced in primary mixed lymphocyte cultures against K/D stimuli require the presence of Lyt 2+ cells but not Lyt 1+ cells Journal of Immunology 125(1): 300-307
Osterud, B.; Kasper, C.K.; Lavine, K.K.; Prodanos, C.; Rapaport, S.I. 1981: Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VIi and bovine tissue factor Thrombosis and Haemostasis 45(1): 55-59
Schmid, D.S.; Rouse, B.T. 1983: Cellular interactions in the cytotoxic T lymphocyte response to herpes simplex virus antigens: differential antigen activation requirements for the helper T lymphocyte and cytotoxic T lymphocyte precursors Journal of Immunology 131(1): 479-484
Moser, G.; Cheng, G.; Abbas, A.K. 1986: Accessory cells in immune suppression. III. Evidence for two distinct accessory cell-dependent mechanisms of T lymphocyte-mediated suppression Journal of Immunology 137(10): 3074-3079
Brach, M.A.; Arnold, C.; Kiehntopf, M.; Gruss, H.J.; Herrmann, F. 1993: Transcriptional activation of the macrophage colony-stimulating factor gene by IL-2 is associated with secretion of bioactive macrophage colony-stimulating factor protein by monocytes and involves activation of the transcription factor NF-kappa B Journal of Immunology 150(12): 5535-5543
Ashman, R.F. 1990: B lymphocyte activation: the transferrin receptor as a prototype intermediate activation molecule Journal of Laboratory and Clinical Medicine 116(6): 759-765